Biocon Completes Acquisition of Minority Shareholders in Biocon Biologics, Boosting Stake to over 98%

Why It Matters

The strategy could lift Biocon into the top tier of global biosimilar producers and accelerate its US market penetration. The insulin capacity boost positions the firm to meet rising diabetes drug demand without additional capital outlays.

Key Takeaways

• Bevacizumab, ustekinumab, Denosumab slated for revenue boost
• Insulin capacity to double by FY27, drug substance FY28
• No new capex except insulin expansion
• US market entry planned for Aflibercept H2 2026
• Q3 FY26 profit surged 475% to ₹144 crore

Pulse Analysis

The biosimilar arena is becoming increasingly crowded as patent cliffs open lucrative pathways for cost‑effective biologics. Biocon’s rollout of bevacizumab, the anti‑VEGF agent, and ustekinumab, a psoriasis treatment, gives it footholds in oncology and immunology, while the pending launch of denosumab targets bone‑loss markets. By securing a 10 % share for ustekinumab already and capturing over 20 % of Turkey’s aflibercept market, Biocon demonstrates the ability to translate regulatory wins into market traction, a critical advantage as it eyes a broader US presence later this year.

Parallel to its biosimilar push, Biocon is scaling insulin production at its Malaysia facility, aiming to double drug‑substance capacity by FY28. This move aligns with the projected surge in global diabetes prevalence, especially in emerging economies where affordable insulin is scarce. By financing the expansion through existing cash flows and avoiding fresh capex, the company preserves balance‑sheet strength while positioning itself to meet long‑term demand, potentially capturing market share from higher‑priced incumbents.

Financially, Biocon’s Q3 FY26 results underscore the payoff of its strategic bets: net profit leapt 475 % to ₹144 crore and revenue climbed to ₹4,290 crore. The near‑complete acquisition of Biocon Biologics consolidates R&D pipelines and streamlines governance, promising cost synergies without aggressive cost‑cutting. For investors, the combination of a robust product pipeline, capacity‑driven growth, and disciplined capital allocation signals a compelling upside narrative as the firm targets higher margins and deeper penetration in the lucrative US biosimilar market.

Deal Summary

Indian pharma giant Biocon Ltd announced it has completed the acquisition of minority shareholders in its subsidiary Biocon Biologics, raising its ownership to more than 98%. The undisclosed‑value transaction finalises the integration of the biologics unit ahead of its growth plans. The deal was reported on February 13, 2026.